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ABSTRACT   Epstein–Barr virus (EBV) plays a central role in the pathogenesis of post-
transplant lymphoproliferative disorder (PTLD), and EBV reactivation after allogenic 
hematopoietic stem cell transplantation (allo-HSCT) is highly correlated with cytomegalovirus 
(CMV) reactivation, which might be a risk factor for PTLD. We encountered a myelodysplastic 
syndrome patient with PTLD in the central nervous system who experienced sequential 
CMV and EBV reactivation immediately after allo-HSCT. Previous studies have suggested 
relationships between CMV and EBV reactivation and between CMV reactivation and PTLD. 
Our case suggests the importance of CMV monitoring in patients after allo-HSCT to prevent 
PTLD. doi：10.11482/KMJ-E201945097　(Accepted on October 23, 2019)




   T h e  d e v e l o p m e n t  o f  p o s t - t r a n s p l a n t 
lymphoproliferative disorder (PTLD) following 
allogenic hematopoietic stem cell transplantation 
(allo-HSCT) is associated with immunosuppression 
caused by T cell depletion of the donor marrow, 
antithymocyte globulin (ATG) use, unrelated or 
HLA-mismatched grafts, acute and chronic graft 
versus host disease (GVHD), and advanced age 
at transplantation１，２）. Epstein–Barr virus (EBV) 
has a central role in the pathogenesis of most 
PTLD cases３）. Immunosuppression results in 
reduced EBV-specific cytotoxic T-lymphocyte 
responses against EBV-infected B-cells, allowing 
the uncontrolled proliferation of EBV-infected 
lymphocytes.  Cytomegalovirus (CMV) has 
major consequences after allo-HSCT, and CMV 
infection itself has been reported to reduce immune 
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Intermediate-2) .  The pat ient  had a history 
of intestinal Behçet's disease and underwent 
sigmoidectomy 2 months prior to the CBT. No 
abnormal findings were noted at admission, during 
which neurological examinations were performed. 
The conditioning regimen consisted of 180 mg/
m2 fludarabine, 3.2 mg/m2 busulfan, and 60 mg/m2 
melphalan, followed by 2.5 mg/kg ATG. The patient 
received 1.89 × 107 cord blood cells per kilogram 
of body weight. Baseline prophylaxis against 
GVHD involved tacrolimus and mycophenolate 
mofetil treatment. Tacrolimus was administered 
intravenously from day –1 at 0.03 mg/kg to day +27, 
where day 0 represents the day of CBT, and it was 
then administered orally after 27 days. A daily dose 
of 1,500 mg of mycophenolate mofetil was also 
administered orally from days 3 to 17. Successful 
engraftment was confirmed on day 15, with no sign 
of acute GVHD during hospitalization.
   On day 45, a CMV antigenemia assay revealed 
function４）. A few studies have suggested that there 
is a relationship between CMV reactivation and 
EBV reactivation４，５）. Zallio F et al. claimed that 
the risk of EBV reactivation in allo-HSCT patients 
is highly related to CMV reactivation, which might 
be a risk factor for PTLD５）. However, the precise 
relationships among CMV/EBV reactivation 
and PTLD are still unknown, and accordingly 
monitoring and treatment strategies are limited. 
Here, we report a rare case of primary central 
nervous system (PCNS)-PTLD, who exhibited 
sequential CMV and EBV reactivation immediately 
after cord blood transplantation (CBT).
CASE REPORT
   The initial features of the patient have been 
reported previously６）. In brief, a 60-year-old 
man underwent CBT in 2010 for myelodysplastic 
syndrome (refractory anemia with excess blasts-1, 
International Prognostic Scoring System (IPSS): 
Fig. 1. Clinical course after cord blood transplantation. An elevation of CMV-DNA in serum was observed 
from day 45, and then the number of lymphocytes increased to respond. Cytomegalovirus was treated with 
ganciclovir and valganciclovir, but re-activated to 292 copies/mL on day 128. Subsequently, the serum 
EBV-DNA level rose to 3.1 × 103 copies/mL on day140, and EBV reactivation was observed. The patient 
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CMV viremia,  which was ini t ia l ly  t reated 
with ganciclovir, followed by valganciclovir 
hydrochloride (Fig. 1). At the same time, an increase 
in peripheral blood lymphocytes was observed. 
These increased lymphocytes were morphologically 
reactive lymphocytes rather than tumor cells, 
then it was seemed to have increased in response 
to cytomegaloviremia. On day 56, the patient 
achieved a hematological recovery and complete 
remission. On day 133, he had a high fever, without 
any neurological symptoms. Subsequently, right 
concomitant deviation with disorientation was 
observed on day 135. Magnetic resonance imaging 
(MRI) of his brain revealed multiple hyperintensity 
regions on day 136 (Fig. 2). Cerebrospinal fluid 
lumbar puncture revealed increased class III atypical 
lymphocytes and his EBV-DNA level in the serum 
and cerebrospinal fluid was 3.1 × 103 and 63.0 × 
103 copies/mL, respectively. Based on these results, 
the patient was diagnosed with PCNS-PTLD. 
   The patient was administered 375 mg/m2 of 
rituximab therapy on day 138, and intrathecal 
chemotherapy with 40 mg of cytarabine and 10 
mg of prednisolone was performed on day 144. 
However, no significant clinical therapeutic effect 
was obtained. The MRI performed on day 149 
showed enlargement of the hyperintensity area, so 
the disease was apparently progressing (Fig. 2). 
The patient was additionally treated with rituximab 
therapy. However, the patient went into respiratory 
failure due to a cerebral herniation and died on day 
156 after CBT. 
   An autopsy was performed with the approval of 
his family. The autopsy macroscopically revealed 
a markedly enlarged left cerebral hemisphere, with 
an increased brain weight to 1,550 g (Fig. 3A, 
3B), hepatosplenomegaly, pleural effusion, ascites, 
sporadic pulmonary masses, and sporadic erosion 
of the digestive tract. In microscopic examination 
of tissues, abnormal lymphocyte proliferation was 
observed in the left cerebral hemisphere region 
(Fig. 3C, 3D). These lymphocytes were positive 
Fig. 2. Fluid-attenuated inversion recovery-magnetic resonance imaging (FLAIR-MRI) of the patient. 
From the left side, MRI before CBT (A), MRI at day 139 (B), and MRI at day 146 (C) are shown. MRI 
clearly indicates the rapid progression of the disease. 
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for CD79a and EBV-encoded small RNA (EBER) 
(Fig. 3E, 3F), but negative for CD3 by immune-
histological staining. From these results, the patient 
was diagnosed as EBV-associated monomorphic 
PTLD involving the brain, lung, digestive tract, and 
adrenal glands. 
DISCUSSION
   The incidence of PTLD in stem cell allograft 
recipients is reported to be 1–2%７）. The risk 
of early-onset PTLD (<1 year) is highest with 
unrelated or HLA-mismatched related donors, 
selective T-cell depletion of donor bone marrow, 
and the use of ATG or anti-CD3 monoclonal 
antibodies７）. PTLD isolated to the CNS following 
allo-HSCT is a rare presentation of an uncommon 
disease. Since the first report by Verschuur A et 
al., 13 cases of PCNS-PTLD related to HSCT 
have been recorded in the literature２，８）, and these 
reports do not indicate a relationship between CMV 
reactivation and the development of PTLD. Seven 
out of 13 previous PCNS-PTLD patients died after 
disease progression or during treatment２）. Similar 
to our patient, three of the seven patients had an 
aggressive clinical course and died within 1 month 
after the development of symptoms２）, emphasizing 
the difficulty of treating this disease. Because 
PCNS-PTLD following transplantation is rare, there 
is no consensus regarding the optimal treatment. 
   The etiology of PTLD is strictly related to EBV 
reactivation; therefore, a pre-emptive strategy may 
be effective. Zallio F et al. reported that among 
101 consecutive patients who underwent allo-
HSCT, 50 patients were CMV-positive after HSCT, 
Fig. 3. Brain autopsy findings of the patient. A: Markedly enlarged left cerebral hemisphere. B: Markedly 
expansion of left cerebral hemisphere. C: Abnormal lymphocyte proliferation was observed in the left cerebral 
hemisphere region (magnification, x100). D: Medium-sized abnormal lymphocytes were diffusely proliferated 
(magnification, x400). These lymphocytes were positive for CD79a (E) and EBV-encoded small RNA (F) by 
immune-histological staining (magnification, x200).
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EBV reactivation was observed in 34 patients, and 
16 patients were at a high risk for progression to 
PTLD, defined as serum EBV-DNA>10,000 copies/
mL５）. Variations in the time until the development 
of PCNS-PTLD, with a median of 4.4 years in 
solid organ transplantation patients３） and 7 months 
following allo-HSCT２）, makes it difficult to apply 
this strategy to the prevention of PCNS-PTLD. 
Zallio F et al. suggested the importance of CMV 
monitoring, as an indicator of EBV reactivation, and 
the effective prevention of PTLD by pre-emptive 
rituximab therapy５）. None of the patients in this 
previous study developed PTLD after a single 
infusion of 375 mg/m2 rituximab, indicating that 
the strategy seems to be effective, and unfortunately, 
our case reinforced the significance of their strategy. 
   The clinical course of our case suggests a 
relationship between CMV reactivation and 
subsequent EBV reactivation prior to the onset of 
PCNS-PTLD. Patients with higher human C-C 
chemokine receptor 5 (CCR5) expression are 
significantly more likely to exhibit EBV reactivation 
after allogeneic HSCT９）. Additionally, CMV 
has been reported to upregulate the expression of 
CCR5 in central memory cord blood mononuclear 
cells10）, which might explain our observation that 
PTLD occurred soon after CMV reactivation in 
a patient who received CBT. From these results, 
monitoring of CMV reactivation can predict EB 
virus reactivation, and early treatment intervention 
may prevent the development of PTLD. 
   Rituximab is considered to have poor efficacy 
against CNS lesions due to its low penetration of 
the blood–brain barrier; therefore, it is unclear 
whether a pre-emptive strategy could prevent the 
development of PCNS-PTLD. 
   In conclusion, the EBV reactivation and PTLD 
occurred shortly after CMV viremia following 
CBT in our patient, suggesting a need for further 
studies on the relationship between sequential 
CMV and EBV reactivation after allo-HSCT and 
the occurrence of EBV-related PTLD, especially in 
patients who received CBT. Optimal strategies for 
the diagnosis and treatment of PCNS-PTLD after 
allo-HSCT remain to be determined. 
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